ISSN 0564-3783  
Main page
Contacts
Preview papers  
Contents  
Themes
Subscription
Information to authors
Editorial board
Standard version



Export citations   UNIMARC   BibTeX   RIS


The apoB genotype and the efficacy of hypolipidemic therapy

Tseluyko V.I., Kravchenko N.A., Chernyshov V., Maksimova N.A., Nazarenko I.L.

 




Several men were examined for association between restriction fragment length polymorphism (RELP) Xba I (exon 26) number of tandem repeats in 3-hypervariable region of the apolipoprotein-B gene and serum levels of cholesterol and triglyceride. These two types of polymorphism were studied. An association of the Xba I site and alleles containing more repeats in the 3-hypervariable region with higher cholesterol and triglyceride was observed. 32 patients with CHD aged 24-56 years were examined. All the patients are males with clinical picture of CHD (stable angina pectoris of II-III functional classes) and dyslipoproteinemia of II a, II b and IV types by D. S. Fredrickson. Xba-I polymorphism of apo-B gene was detected by DNA polymerase reaction method. The following Xba-I genotypes were distinguished: X1X1 (absence of Xba I site); X1X2 (heterozygosity on Xba I site) and X2X2 (homozygosity on Xba-I site). Lipantil (fenofibratte) was prescribed in a dose of 300 mg daily after meals (100 mg three times a day). Data obtained show that DNA polymorphism of apo-B gene not only influences plasma lipids concentration but also determines effectiveness of hypolipidemic therapy. Hypolipidemic effect of lipantil depends on Xba-I site presents in apo-B gene and is significantly expressed in homozygous patients with X1X1 genotype.

Tsitologiya i Genetika 1998, vol. 32, no. 1, pp. 126-134



Tseluyko V.I., Kravchenko N.A., Chernyshov V., Maksimova N.A., Nazarenko I.L. The apoB genotype and the efficacy of hypolipidemic therapy, Tsitol Genet., 1998, vol. 32, no. 1, pp. 126-134.




Copyright© ICBGE 2002-2021 Coded & Designed by Volodymyr Duplij Modified 25.10.21